Table 3A.
The expressions of 31 macrophage markers in 10 Mφ subsets are modulated in 8 groups of 34 diseases.
| Mφ | Autoimmune diseases | Cardiovascular diseases | Digestive inflammatory | Infection diseases | Metabolic diseases | Respiratory diseases | Digestive tumors | Other tumors | Up-regulated disease | Down-regulated disease | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subsets | Markers | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Number | % | Number | % |
| M1 | IL1B | ↓ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↑ | ↑ | ↓ | ↓ | 8 | 23.5 | 7 | 20.6 | |||||||||||||||||||
| TNF | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | ↓ | ↑ | ↑ | ↓ | 6 | 17.6 | 5 | 14.7 | ||||||||||||||||||||||||
| IL6 | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | ↑ | ↓ | ↓ | 8 | 23.5 | 5 | 14.7 | ||||||||||||||||||||||
| CXCL11 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 15 | 44.1 | 0 | 0.0 | ||||||||||||||||||||
| CXCL10 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 12 | 35.3 | 0 | 0.0 | |||||||||||||||||||||||
| CXCL9 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 13 | 38.2 | 0 | 0.0 | ||||||||||||||||||||||
| IL23A | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | 9 | 26.5 | 3 | 8.8 | |||||||||||||||||||||||
| IL12A | ↑ | ↑ | ↓ | ↑ | ↓ | 3 | 8.8 | 2 | 5.9 | ||||||||||||||||||||||||||||||
| IL12B | ↑ | ↓ | ↑ | ↑ | 3 | 8.8 | 1 | 2.9 | |||||||||||||||||||||||||||||||
| ARG2 | ↓ | ↑ | ↑ | ↓ | ↓ | ↓ | ↑ | ↓ | ↑ | ↓ | 4 | 11.8 | 6 | 17.6 | |||||||||||||||||||||||||
| M2a | MRC1 | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | 4 | 11.8 | 3 | 8.8 | |||||||||||||||||||||||||||
| CD163 | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | 9 | 26.5 | 6 | 17.6 | ||||||||||||||||||||
| STAB1 | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | 7 | 20.6 | 3 | 8.8 | |||||||||||||||||||||||||
| CCL18 | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | 11 | 32.4 | 2 | 5.9 | ||||||||||||||||||||||
| CD200R1 | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | ↑ | 2 | 5.9 | 5 | 14.7 | ||||||||||||||||||||||||||||
| F13A1 | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | 4 | 11.8 | 7 | 20.6 | ||||||||||||||||||||||||
| IL1RN | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | 15 | 44.1 | 4 | 11.8 | ||||||||||||||||
| ARG1 | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | 8 | 23.5 | 3 | 8.8 | ||||||||||||||||||||||||
| PDE4DIP | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | 6 | 17.6 | 8 | 23.5 | |||||||||||||||||||||
| Chil4 | 0 | 0.0 | 0 | 0.0 | |||||||||||||||||||||||||||||||||||
| Chil3 | 0 | 0.0 | 0 | 0.0 | |||||||||||||||||||||||||||||||||||
| Retnla | 0 | 0.0 | 0 | 0.0 | |||||||||||||||||||||||||||||||||||
| M2b | IL10 | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | 7 | 20.6 | 1 | 2.9 | ||||||||||||||||||||||||||
| IL12B | ↑ | ↑ | ↑ | 3 | 8.8 | 0 | 0.0 | ||||||||||||||||||||||||||||||||
| IL12A | ↑ | ↑ | ↓ | ↑ | ↓ | 3 | 8.8 | 2 | 5.9 | ||||||||||||||||||||||||||||||
| M2c | MRC1 | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | 4 | 11.8 | 3 | 8.8 | |||||||||||||||||||||||||||
| ARG1 | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | 8 | 23.5 | 3 | 8.8 | ||||||||||||||||||||||||
| M2d | TNF | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | ↑ | ↓ | 5 | 14.7 | 4 | 11.8 | |||||||||||||||||||||||||
| IL12A | ↑ | ↑ | ↓ | ↑ | ↓ | 3 | 8.8 | 2 | 5.9 | ||||||||||||||||||||||||||||||
| IL12B | ↑ | ↓ | ↑ | ↑ | 3 | 8.8 | 1 | 2.9 | |||||||||||||||||||||||||||||||
| M4 | MMP7 | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | 10 | 29.4 | 2 | 5.9 | ||||||||||||||||||||||
| MRC1 | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | 4 | 11.8 | 3 | 8.8 | ||||||||||||||||||||||||||||
| S100A8 | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↓ | ↓ | 7 | 20.6 | 4 | 11.8 | ||||||||||||||||||||||||
| Mox | HMOX1 | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↓ | ↓ | ↑ | 9 | 26.5 | 4 | 11.8 | |||||||||||||||||||||
| NFE2L2 | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | 3 | 8.8 | 7 | 20.6 | |||||||||||||||||||||||||
| TXNRD1 | ↑ | ↑ | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ | 5 | 14.7 | 3 | 8.8 | |||||||||||||||||||||||||||
| SRXN1 | ↑ | ↑ | ↑ | ↑ | ↓ | ↑ | ↑ | ↑ | ↑ | 8 | 23.5 | 1 | 2.9 | ||||||||||||||||||||||||||
| M(hb) | CD163 | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | 9 | 26.5 | 6 | 17.6 | |||||||||||||||||||
| MRC1 | ↓ | ↑ | ↑ | ↓ | ↑ | ↓ | ↑ | 4 | 11.8 | 3 | 8.8 | ||||||||||||||||||||||||||||
| Mhem | CD163 | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | 9 | 26.5 | 6 | 17.6 | |||||||||||||||||||
| HA-mac | CD163 | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | 9 | 26.5 | 6 | 17.6 | |||||||||||||||||||
| HLA-DRB1 | ↑ | ↓ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↓ | ↑ | 6 | 17.6 | 4 | 11.8 | |||||||||||||||||||||||||
| HLA-DRA | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↑ | ↑ | ↓ | ↑ | 7 | 20.6 | 3 | 8.8 | |||||||||||||||||||||||||
| Up- regulated gene |
Number | 8 | 3 | 5 | 0 | 16 | 20 | 1 | 1 | 8 | 12 | 12 | 16 | 3 | 8 | 3 | 0 | 2 | 3 | 0 | 0 | 2 | 6 | 0 | 8 | 6 | 5 | 8 | 6 | 11 | 8 | 1 | 12 | 3 | 12 | ||||
| % | 25.8 | 9.7 | 16.1 | 0.0 | 51.6 | 64.5 | 3.2 | 3.2 | 25.8 | 38.7 | 38.7 | 51.6 | 9.7 | 25.8 | 9.7 | 0.0 | 6.5 | 9.7 | 0.0 | 0.0 | 6.5 | 19.4 | 0.0 | 25.8 | 19.4 | 16.1 | 25.8 | 19.4 | 35.5 | 25.8 | 3.2 | 38.7 | 9.7 | 38.7 | |||||
| Down-regulated gene | Number | 4 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 2 | 1 | 8 | 1 | 4 | 3 | 4 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 6 | 2 | 10 | 1 | 5 | 3 | 3 | 3 | 12 | 4 | ||||
| % | 12.9 | 0.0 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 | 0.0 | 0.0 | 6.5 | 3.2 | 25.8 | 3.2 | 12.9 | 9.7 | 12.9 | 0.0 | 3.2 | 6.5 | 0.0 | 3.2 | 3.2 | 0.0 | 19.4 | 6.5 | 32.3 | 3.2 | 16.1 | 9.7 | 9.7 | 9.7 | 38.7 | 12.9 | |||||
First, some Mϕ markers were upregulated in more than 30% of the 34 diseases, including three M1 markers, CXCL11, CXCL10, and CXCL9, 2 M2 markers, CCL18 and IL1RN, and one M4 marker, MMP7. Second, the diseases having Mϕ markers upregulated in more than 30% of the 34 diseases were of eight types, namely #5 myocardial infarction, #6 coronary artery disease, #10 gastritis, #11 Crohn's ileitis, #12 Crohn's colitis, #29 esophageal cancer, #32 ovarian carcinoma, and #34 renal carcinoma (For detailed expression data, see Figures S9–S12). 1, Rheumatoid arthritis; 2, Systemic lupus erythematosus; 3, Psoriasis; 4, Asthma; 5, Myocardial infarction; 6, Coronary artery disease; 7, Abdominal aortic aneurysm; 8, Aortic occlusive disease; 9, Ulcerative colitis; 10, Gastritis; 11, Crohn's ileitis; 12, Crohn's colitis; 13, Tuberculous Meningitis coinfected with HIV; 14, Sepsis; 15, Chronic Hepatitis C virus; 16, Tuberculosis; 17, Type 2 diabetes; 18, Type 1 diabetes; 19, Metabolic syndrome; 20, Familial Hypercholesterolemia; 21, Chronic obstructive pulmonary disease; 22, Pulmonary arterial hypertension; 23, Asthma; 24, Pneumonia; 25, Gastric adenocarcinoma; 26, Hepatocellular cancer; 27, Colorectal adenocarcinoma; 28, Pancreatic cancer; 29, Esophageal cancer; 30, Breast Adenocarcinoma; 31, Prostate cancer; 32, Ovarian carcinoma; 33, Lung cancer; 34, Renal carcinoma.